These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1022 related items for PubMed ID: 16730272

  • 1. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 2. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 3. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P, Bundred N.
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
    Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA.
    J Clin Oncol; 2007 Mar 01; 25(7):829-36. PubMed ID: 17159193
    [Abstract] [Full Text] [Related]

  • 5. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M.
    Breast; 2006 Feb 01; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA.
    Clin Breast Cancer; 2009 May 01; 9(2):77-85. PubMed ID: 19433387
    [Abstract] [Full Text] [Related]

  • 7. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 11. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P.
    Breast; 2007 Dec 01; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [Abstract] [Full Text] [Related]

  • 12. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.
    Clin Breast Cancer; 2012 Feb 01; 12(1):40-8. PubMed ID: 22014381
    [Abstract] [Full Text] [Related]

  • 13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 01; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 14. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD.
    Breast Cancer Res Treat; 2011 Dec 01; 130(3):863-70. PubMed ID: 21861101
    [Abstract] [Full Text] [Related]

  • 15. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 16. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM.
    Oncologist; 2008 Feb 01; 13(2):187-95. PubMed ID: 18305064
    [Abstract] [Full Text] [Related]

  • 17. Management of bone loss induced by aromatase inhibitors.
    Gnant M.
    Cancer Invest; 2006 Feb 01; 24(3):328-30. PubMed ID: 16809162
    [Abstract] [Full Text] [Related]

  • 18. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE.
    Cancer Treat Rev; 2008 Feb 01; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [Abstract] [Full Text] [Related]

  • 19. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.
    Bone; 2006 Oct 01; 39(4):787-95. PubMed ID: 16844441
    [Abstract] [Full Text] [Related]

  • 20. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 01; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.